Αποτελέσματα Αναζήτησης
Influenza activity started in week 47/2017 and returned to baseline levels in week 18/2018. Influenza viruses circulated at high levels between weeks 51/2017 and 13/2018. This is longer than in recent seasons and may have contributed to the severity of this season.
27 Οκτ 2023 · Seasonal influenza is a vaccine-preventable disease and annual influenza vaccinations are the most effective ways to prevent influenza. ECDC continues to emphasise that all Europeans who are recommended to have the influenza vaccine should get vaccinated.
3 Μαρ 2018 · Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A (H1N1)pdm09, −42 to 7% against influenza A (H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Fluzone is typically administered in a single dose by intramuscular injection; [20] an intradermal injection is also available. [21] It is presented as a 0.25 ml syringe for pediatric use, as a 0.5 ml syringe for adults and children, as a 0.5 ml vial for adults and children, and as a 5 ml vial for adults and children. [ 20 ]
Summary and recommendations. The influenza epidemic period for the European Region started in week 48/2017 and by week 1/2018 one third of Member States reported that 30% or more of their sentinel specimens were testing positive for influenza viruses[1].
Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A (H1N1)pdm09, -42 to 7% against influenza A (H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32–43% against influenza A; higher against A (H1N1)pdm09 and lower against A (H3N2). Among hospitalised older adults, VE estimates were 34–38% against influenza A and slightly lower against A (H1N1)pdm09.
